Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 12% Improvement Relative Risk Mortality (b) 57% c19hcq.org Hernandez-Cardenas et al. HCQ RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? RCT 214 patients in Mexico No significant difference in mortality Hernandez-Cardenas et al., medRxiv, doi:10.1101/2021.02.01.21250371 Favors HCQ Favors control
Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial
Hernandez-Cardenas et al., medRxiv, doi:10.1101/2021.02.01.21250371 (Preprint)
Hernandez-Cardenas et al., Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled.., medRxiv, doi:10.1101/2021.02.01.21250371 (Preprint)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Very late stage RCT with 214 patients, mean SpO2 65%, 162 on mechanical ventilation, showing no significant difference in mortality.
Patients not intubated at baseline show greater improvement, HR 0.43 [0.09-2.03].
Table 4 shows different results to the abstract - table 4 adjusted HR 0.80 [0.51-1.23], abstract HR 0.88 [0.51-1.53]. There was no significant difference in severe adverse events.
risk of death, 12.0% lower, RR 0.88, p = 0.66, treatment 106, control 108.
risk of death, 57.0% lower, RR 0.43, p = 0.29, subgroup not intubated at baseline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hernandez-Cardenas et al., 5 Feb 2021, Randomized Controlled Trial, Mexico, preprint, 6 authors, average treatment delay 7.4 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.02.01.21250371; this version posted February 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . HCQ for severe COVID-19 HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL AUTHORS: Carmen Hernandez-Cardenas1, Ireri Thirion-Romero1, Norma E. RiveraMartinez2, Patricia Meza-Meneses3, Arantxa Remigio-Luna1, Rogelio Perez-Padilla1 on behalf of the Research Group on hydroxychloroquine for COVID-19 * *The research group also formed by Drs. Luis Felipe Jurado-Camacho1, Sebastián RodríguezLlamazares1, Teresa Aguirre-Pérez1, Joel Armando Vásquez-Pérez1, and Alejandra RamirezVenegas1, from the Instituto Nacional de Enfermedades Respiratorias Mexico City, and Drs. Gabriela Tapia-Pastrana2, Nestor G. Cruz-Ruiz2 from the Hospital de Referencia de Alta Especialidad Oaxaca. 1- Instituto Nacional de Enfermedades Respiratorias; CP 14080, Mexico City, Mexico. 2- Hospital Regional de Alta Especialidad Oaxaca; CP 71256, Oaxaca, Mexico. 3-Hospital Regional de Alta Especialidad Ixtapaluca; CP 53560, Edo de México, Mexico. Correspondence: Dr. Rogelio Perez Padilla, Instituto Nacional de Enfermedades Respiratorias, Mexico City. e-mail perezpad@gmail.com 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.02.01.21250371; this version posted February 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . HCQ for severe COVID-19 ABSTRACT The novel coronavirus pandemic (COVID–19) represents a major public health problem due to its rapid spread and its ability to generate severe pneumonia. Thus, it is essential to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo. Material and methods: A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events. Results: A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% ± 20, tachycardic (pulse rate 108±17 min-1) and tachypneic (32 ±10 min-1); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit